两种生物碱抑制剂: α-淀粉酶的动力学及分子模拟研究

doi:10.5246/jcps.2015.02.009

中国药学(英文版) ›› 2015, Vol. 24 ›› Issue (2): 80-87.DOI: 10.5246/jcps.2015.02.009

两种生物碱抑制剂: α-淀粉酶的动力学及分子模拟研究

梁毅¹, 裴芬², 王弘^1*, 陈世忠^1*

1. 北京大学医学部药学院天然药物化学系, 北京 100191,
2. 北京大学医学部药学院天然药物及仿生药物国家重点实验室, 北京 100191

收稿日期:2014-06-30 修回日期:2014-09-28 出版日期:2015-02-01 发布日期:2014-11-24
通讯作者: Tel./Fax: 86-10-82802723, 86-10-82801559
基金资助:
State Key Laboratory of Natural and Biomimetic Drugs 2013 Funded Project “Establishment and Application an Online Natural Medicines System with Efficient Separation, Structural Identification and Activity Detection”.

Two alkaloids as α-amylase inhibitors: enzyme kinetics and molecular modeling investigations

Yi Liang¹, Fen Pei², Hong Wang^1*, Shizhong Chen^1*

1. Department of Natural Medicines, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
2. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Received:2014-06-30 Revised:2014-09-28 Online:2015-02-01 Published:2014-11-24
Contact: Tel./Fax: 86-10-82802723, 86-10-82801559
Supported by:
State Key Laboratory of Natural and Biomimetic Drugs 2013 Funded Project “Establishment and Application an Online Natural Medicines System with Efficient Separation, Structural Identification and Activity Detection”.

摘要/Abstract

摘要：

用2-氯-4-硝基-α-半乳糖麦芽糖苷(Gal-G2-α-CNP)作底物研究猪胰腺淀粉酶抑制剂: 白屈菜碱和吴茱萸次碱的抑制效力。首次报道白屈菜碱和吴茱萸次碱抑制淀粉酶的活性, 并用动力学方法研究其抑制猪胰腺淀粉酶的抑制剂的类型。结果表明在使用Gal-G2-α-CNP作为底物时, 两种抑制剂均为混合非竞争型抑制剂, 且一分子的抑制剂只与一分子的酶结合。用二次作图计算的动力学常数分别为:白屈菜碱, K_EI: 0.9 mM, K_ESI: 0.04 mM; 吴茱萸次碱, K_EI: 3.5 mM, K_ESI: 0.31 mM。这说明白屈菜碱和吴茱萸次碱更倾向于竞争型抑制剂。用GOLD软件进行分子对接, 结果显示, 阿卡波糖与Glu²³³, Lys²⁰⁰和His³⁰⁵氨基酸残基有氢键作用, 而白屈菜碱与Glu²³³, Lys²⁰⁰和His³⁰⁵有氢键作用, 吴茱萸次碱只与Lys²⁰⁰有氢键作用。研究结果表明白屈菜碱和吴茱萸次碱作为淀粉酶抑制剂应用的前景良好, 且白屈菜碱的抑制作用强于吴茱萸次碱。

关键词: α-淀粉酶抑制剂, 动力学分析, 分子对接, 白屈菜碱, 吴茱萸次碱

Abstract:

In the present study, we studied the inhibitory effects of chelidonine and rutaecarpin on porcine pancreatic α-amylase (PPA) catalyzed hydrolysis using 2-chloro-4-nitrophenyl-4-O-β-D-galactopyranosylmaltoside (Gal-G2-α-CNP). We, for the first time, provided kinetic report and detailed inhibitory effects of both compounds on PPA. Lineweaver-Burk plot revealed that the inhibition was a mixed-noncompetitive type, and only one molecule of inhibitor bound to the enzyme or to the enzyme-substrate complex. Kinetic constants calculated from secondary plots were in millimole range. Dissociation constants of enzyme-inhibitor complex (K_EI) were 0.9 mM and 3.5 mM, respectively. Moreover, dissociation constants of enzyme-inhibitor-substrate complex (K_E_SI) were 0.04 mM and 0.31 mM, respectively. These data indicated that the inhibition was more inclined to competitive to Gal-G2-α-CNP hydrolysis. Further molecular docking study manifested that hydrogen bonding formed between acarbose and aspartic acid (Asp³⁰⁰), histidine (His³⁰⁵) and glycine (Gly³⁰⁶), while hydrogen bonding was observed between chelidonine and glutamic acid (Glu²³³), lysine (Lys²⁰⁰) and His³⁰⁵. In addition, rutaecarpine had only one hydrogen bond with Lys²⁰⁰. Our data indicated that chelidonine and rutaecarpine were two promising drug candidates, and chelidonine possessed stronger inhibitory effect compared with rutaecarpine.

Key words: α-Amylase inhibitors, Kinetic analysis, Molecular modeling, Chelidonine, Rutaecarpine

中图分类号:

R917

Supporting:

梁毅, 裴芬, 王弘, 陈世忠. 两种生物碱抑制剂: α-淀粉酶的动力学及分子模拟研究[J]. 中国药学(英文版), 2015, 24(2): 80-87.

Yi Liang, Fen Pei, Hong Wang, Shizhong Chen. Two alkaloids as α-amylase inhibitors: enzyme kinetics and molecular modeling investigations[J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(2): 80-87.

参考文献

[1] WHO (2002). Traditional medicine strategy 2002-2005. WHO Publications, pp. 1-6.

[2] Bischoff, H. Eur. J. Clin. Invest. 1994, 24, 3-10.

[3] Tortora, G.J.; Derrickson, B. Principles of anatomy & physiology (13th edition). New Jersey, John Wiley & Sons, Inc. 2011: 1000

[4] Henrissat, B. Biochem. J. 1991, 280, 309-316.

[5] Miller, G.L. Anal. Chem. 1959, 31, 426-428.

[6] Morishita, Y.; Iinuma, Y.; Nakashima, N.; Majima, K.; Mizuguchi, K.; Kawamura, Y. Clin. Chem. 2000, 46, 928-933.

[7] Zajácz, Á.; Gyémánt, G.; Vittori, N.; Kandra, L. Carbohyd. Res. 2007, 342, 717-723.

[8] Kawano, A.; Tanaka, Y.; Ishitobi, Y.; Maruyama, Y.; Ando, T.; Inoue, A.; Okamoto, S.; Imanaga, J.; Kanehisa, M.; Higuma, H.; Ninomiya, T.; Tsuru, J.; Akiyoshi, J. Psychiat. Res. 2013, 209, 85-90.

[9] Ieda, M.; Miyaoka, T.; Wake, R.; Liaury, K.; Tsuchie, K.; Fukushima, M.; Araki, T.; Ezoe, S.; Inagaki, T.; Horigu, J. Eur. Arch. Psychiatry. Clin. Neurosci. 2014, 264, 83-87.

[10] Tanaka, Y.; Ishitobi, Y.; Maruyama, Y.; Kawano, A.; Ando, T.; Okamoto, S.; Kanehisa, M.; Higuma, H.; Ninomiya, T.; Tsuru, J.; Hanada, H.; Kodama, K.; Isogawa, K.; Akiyoshi, J. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2012, 36, 220-224.

[11] Murao, S.; Goto, A.; Matsui, Y.; Ohyama, K. Agric. Biol. Chem. 1980, 44, 1679-1681.

[12] Murao, S.; Oouchi, N.; Goto, A.; Arai, M. Agric. Biol. Chem. 1983, 47, 453-454.

[13] Eichler, H.G.; Korn, A.; Gasic, S.; Pirson, W.; Businger. J. Diabetologia. 1984, 26, 278-281.

[14] Svensson, B.; Fukuda, K.; Nielsen, P.K.; Bønsager, B.C. Biochim.Biophys.Acta. 2004, 1696, 145-156.

[15] Kim, J.S.; Kwon, C.S.; Son, K.H. Biosci. Biotechnol. Biochem. 2000, 64, 2458-2461.

[16] Tadera, K.; Minami, Y.; Takamatsu, K.; Matsuoka, T. J. Nutr. Sci.Vitaminol. 2006, 52, 149-153.

[17] Zhang, J.; Kashket, S. Caries. Res. 1998, 32, 233-238.

[18] He, Q.; Lv, Y.; Yao, K. Food Chem. 2006, 101, 1178-1182.

[19] Funke, I.; Melzig, M.F. Pharmazie. 2005, 60, 796-797.

[20] Tundis, R.; Loizzo, M.R.; Menichini. F. Mini-Rev. Med. Chem. 2010, 10, 315-331.

[21] Fujisawa, T.; Ikegami, H.; Inoue, K.; Kawabata, Y.; Ogihara, T. Metabolism: Clin. Exp. 2005, 54, 387-390.

[22] Singh, S.K.; Rai, P.K.; Jaiswal, D.; Watal, G. Evidence-Based Complem. Altern. Med. 2008, 5, 415-420.

[23] Yamaguchi, M.; Wakasugi, J.; Sakakima, J. Clin. Biochem. 2008, 41, 325-330.

[24] Emily, S.W.; Harold, D.; Gerald, S.; Rodrigo, C. Clin. Chem. 1988, 34, 2005-2008.

[25] Larson, S.B.; Greenwood, A.; Cascio, D.; Day, J.; McPherson, A. J. Mol. Biol. 1994, 235, 1560-1584.

[26] Qian, M.; Haser, R.; Payan, F. J. Mol. Biol. 1993, 231, 785-799.

[27] Brayer, G.D.; Luo, Y.; Withers, S.G. Protein Sci. 1995, 4, 1730-1742.

[28] Brayer, G.D.; Sidhu, G.; Maurus, R.; Rydberg, E.H.; Braun, C.; Wang,Y.; Nguyen, N.T.; Overall, C.M.; Withers, S.G. Biochemistry. 2000, 39, 4778-4791.

[29] Lo Piparo, E.; Scheib, H.; Frei, N.; Williamson, G.; Grigorov, M.; Chou, C.J. J. Med. Chem. 2008, 51, 3555-3561.

两种生物碱抑制剂: α-淀粉酶的动力学及分子模拟研究

Two alkaloids as α-amylase inhibitors: enzyme kinetics and molecular modeling investigations

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	尚平, 刘琳, 方毅. 基于网络药理学和分子对接探讨桂枝茯苓丸治疗子宫内膜异位症的作用机制[J]. 中国药学(英文版), 2023, 32(9): 704-719.
[2]	武东燕, 王小丹, 柴金苗, 李钦青, 李悦, 毕梅, 桂婉威, 曹慧敏. 基于网络药理学及实验验证探究当归补血汤治疗糖尿病性视网膜病变的作用机制[J]. 中国药学(英文版), 2023, 32(7): 527-538.
[3]	敖民, 包明兰, 侯亚星, 月英, 李慧芳, 吴国华, 苏日嘎拉图. 基于网络药理学的蒙药肋柱花抗急性肝损伤作用机制研究[J]. 中国药学(英文版), 2023, 32(4): 268-282.
[4]	李雅静, 白雅雯, 杜宇, 严长宏, 麻春杰, 孙丽宁, 卜凤跃, 严昊阳. 玉屏风散治疗慢性肾小球肾炎的临床疗效评价及作用机制研究[J]. 中国药学(英文版), 2023, 32(12): 1006-1026.
[5]	孙志勇, 高淑丽, 张阳, 薛刚强, 苑子林, 王少男. 基于网络药理学和分子对接技术研究蒲公英治疗乳腺增生的潜在机制[J]. 中国药学(英文版), 2023, 32(11): 893-910.
[6]	周代英, 陈靓, 吕志刚. 基于网络药理学和分子对接探讨灯盏细辛治疗年龄相关性黄斑变性的机制[J]. 中国药学(英文版), 2023, 32(11): 923-934.
[7]	丁宁, 张涛, 罗吉, 刘皓辰, 邓宇, 何永恒. 基于网络药理学和分子对接探究白芍七物汤治疗结直肠癌的作用机制[J]. 中国药学(英文版), 2023, 32(1): 17-31.
[8]	伊帕尔古丽·阿皮孜, 王昭志, 贺宏吉, 李喆喆, 王梅. 基于网络药理学和分子对接探讨骆驼蓬种子抗肝癌作用机制[J]. 中国药学(英文版), 2022, 31(7): 517-529.
[9]	商燕, 蔺晓源, 张田田, 谢丽华, 胡国恒. 基于网络药理学和分子对接探讨益气活血方抗脑缺血机制研究[J]. 中国药学(英文版), 2022, 31(2): 117-133.
[10]	都晓辉, 杨宏艳, 王涛, 崔红霞, 林宇, 李宏铃. 基于网络药理学和分子对接技术解读川皮苷改善代谢综合征的作用机制[J]. 中国药学(英文版), 2022, 31(11): 803-823.
[11]	杨雁芳, 张伊楠, 张友波, 杨秀伟. 液质联用法测定吴茱萸碱、吴茱萸次碱、去氢吴茱萸碱在大鼠脑脊液和脑组织中的分布[J]. 中国药学(英文版), 2022, 31(1): 13-22.
[12]	高太祥, 赵峰, 石莉尧, 王瑞. 基于网络药理学和分子对接技术探讨附子汤治疗慢性心力衰竭的作用机制[J]. 中国药学(英文版), 2021, 30(9): 705-715.
[13]	李成, 朱玉华, 孙晓旻, 许静, 熊丹, 王娟, 高新庐, 陈绪龙. 基于网络药理学和分子对接技术探讨雷公藤致急性肾损伤的多重作用机制[J]. 中国药学(英文版), 2021, 30(7): 556-569.
[14]	李哲, 丁媛, 黄浩, 王可馨, 吴嘉仪, 朱琳, 廖正根, 明良山. 近红外光谱和混料实验设计研究β-环糊精差异化包封挥发油成分: 以包合α-蒎烯、月桂烯和3-蒈烯为例[J]. 中国药学(英文版), 2021, 30(6): 524-537.
[15]	靳玉瑞, 李爱秀, 康家雄. 基于2009 H1N1神经氨酸酶天然产物抑制剂的作用模式的研究[J]. 中国药学(英文版), 2020, 29(6): 390-397.